Navigation Links
Aida's Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer
Date:10/22/2007

SANTA MONICA, Calif., Oct. 22 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) today announced an update on its testing of Rh-Apo2L, the next large-scale product to be launched by the Company into the China market. Aida previously announced that it had successfully passed its Phase I tests in July 2006, which consists of tests for safety, dosage and the potential cancer treatments to be tested in Phases II & III. Aida is currently undergoing Phase II testing of Rh-Apo2L testing through China's SFDA, the national drug regulatory agency.

Phase II is divided into two substages: IIA and IIB. IIA consists of tests on over 100 human patients using only Rh-Apo2L and gauges the efficacy of the drug as well as the narrowing of the scope of targeted cancers. Results thus far have shown strong efficacy in treating lung cancer (non-small cell), non-Hodgkins lymphoma, stomach cancer, pancreatic cancer and kidney cancer. Shanghai Qiaer, Aida's research subsidiary, has reduced the key cancer targets to the three main diseases which Rh-Apo2L has shown the most efficacy and which have the most market potential. These three cancer targets will be announced at a later date, pending successful trials. Formal results will also be released after clinical tests are completed.

Phase IIB is testing Rh-Apo2L in combination with other anti-cancer drugs on the above three chosen diseases. The tests monitor interaction with other drugs, side effects and dosages for additional tests. To date, the combined use of Rh-Apo2L with selected anti-cancer drugs has shown good efficacy, reliable safety and no additional side effects. Tests are still ongoing for various dosage amounts on different types of cancer and no regulatory approval has been received for these drugs.

About Rh-Apo2L -- The Anti-Cancer Drug

Rh-Apo2L is a pioneering biotechnology gene therapy drug used to treat certain forms of cancer. This biopharmaceutical drug has gained
'/>"/>

SOURCE Aida Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3

Related biology technology :

1. BioRobot MDx standardize your automated protocols in clinical laboratories
2. What patients want: A story of choice, clinical trials & evidence-based medicine
3. ZyStor seeks to raise $15M for clinical trials
4. Prodesse begins clinical trials for flu virus detection
5. ConjuGon raises $3.3 million to fund clinical trials
6. Cancer-fighting agent heads for clinical trials
7. Quintessence cancer treatment chosen for clinical studies
8. Third Wave reports clinical growth, continued loss
9. Childrens expanding use of Sunrise Clinical Manager
10. Life-sciences conference to feature novel research with clinical potential
11. $14 million grant to drive clinical research at UW
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)NEW YORK, Dec. 4 Stemline Therapeutics, Inc. today announced that data from pre-clinical studies of its IL-3R targeting agents, SL-401 and SL-501, in both in vitro and animal models of human chroni
(Date:12/3/2009)DALLAS, Dec. 3 ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a deb
(Date:12/3/2009)WALTHAM, Mass., Dec. 3 Inverness Medical Innovations, Inc. (NYSE: IMA ), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and h
(Date:12/2/2009)MANILA, Philippines, Dec. 2 Spectrum Blue Steel is emerging as one of the fastest growing green energy companies on the planet. Through the efforts of True Green Energy Group and True Green Planet,s
Breaking Biology Technology:Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 2Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 3
...ns an Important Option for Women Seeking Relief of...LLEGEVILLE, Pa., March 4 Observational,follow-up ...y published,today in the Journal of the American M...ht into the appropriate use of hormone therapy whe...l women. Wyeth Pharmaceuticals, a,division of Wyet...
...e Board of Directors of,Bristol-Myers Squibb Compa...nd of thirty-one cents ($0.31) per share on the $....quarterly dividend will be payable on May 1,2008, ... on April 4, 2008., The Directors also declared a...re on the $2.00 Convertible Preferred Stock of the...
...h 4 Osteotech, Inc.,(Nasdaq: OSTE ), a leader in...nerative medicine, announced today that the Food a...(k) submission for its Plexur,M(TM) Biocomposite. ...ology, Plexur M(TM) is intended for use in filling...e not intrinsic to the stability of the bony,struc...
Other Biology Technology:WHI Findings Published in JAMA Do Not Affect Clinical Guidance for the Appropriate Use of Hormone Therapy 2WHI Findings Published in JAMA Do Not Affect Clinical Guidance for the Appropriate Use of Hormone Therapy 3WHI Findings Published in JAMA Do Not Affect Clinical Guidance for the Appropriate Use of Hormone Therapy 4Osteotech Receives FDA Clearance for Plexur M(TM) Biocomposite 2Osteotech Receives FDA Clearance for Plexur M(TM) Biocomposite 3
(Date:12/4/2009)Scientists from the Royal Botanic Gardens, Kew and the Natural History Museum believe that carnivorous behaviour in plants is far more widespread than previously thought, with many commonly grown plan
(Date:12/4/2009)A major discovery is challenging accepted thinking about amyloids the fibrous protein deposits associated with diseases such as Alzheimer,s and Parkinson,s and may open up a potential new area for t
(Date:12/3/2009)The extinction of plant and animal species can be likened to emptying a museum of its collection, or dumping a cabinet full of potential medicines into the trash, or replacing every local cuisine with
Breaking Biology News(10 mins):Scientists think 'killer petunias' should join the ranks of carnivorous plants 2New therapy targets for amyloid disease 2Species down, disease up 2Species down, disease up 3Species down, disease up 4Inverness Medical Innovations Proposes to Acquire Concateno plc 48040 1Inverness Medical Innovations Proposes to Acquire Concateno plc 48040 2Inverness Medical Innovations Proposes to Acquire Concateno plc 48040 3Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference 12484 1Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference 12484 2Compressus Initiates Enterprise Workflow Management Implementation at Radiology Associates of Fox Valley 48037 1Compressus Initiates Enterprise Workflow Management Implementation at Radiology Associates of Fox Valley 48037 2Compressus Initiates Enterprise Workflow Management Implementation at Radiology Associates of Fox Valley 48037 3
...rs are more attractive to women seeking short-term...verpool have found. , It was previously assumed t...ve facial feature and in non-Western cultures they.... Scientists at Liverpool and Stirling University...ring on men attractive and may associate it with h...
... 18, 2008 The American Journal of Preventive Medi...08), will be featured at the "Changing Climate Ch...ading off the event is Guest Editor Howard Frumkin...change on human health. , "Climate change is a ke...ed to understand the consequences of climate chang...
...ornia--Off the coast of Central California, in the...tal pyramid about the size of two compact cars sit...l pyramid is the heart of the Monterey Accelerated...servatory offshore of the continental United State...ng, the MARS Observatory went "live" on Monday, No...
Other Biology News:Scientists find facial scars increase attractiveness 2Issues at intersection of climate change and health impact global well-being 2Issues at intersection of climate change and health impact global well-being 3Issues at intersection of climate change and health impact global well-being 4New deep-sea observatory goes live 2New deep-sea observatory goes live 3New deep-sea observatory goes live 4
Adaptor for ABI 3700 (AB-0800) from ABgene
...eta Synuclein Synucleins are small, soluble prote...rtain tumors. The family includes three known prot...ynuclein. The alpha and beta synuclein proteins ar...seen mainly in presynaptic terminals. Immunogen:...
...fic for human cardiac troponin subunit T, a 31kDa ...gnals responsible for contraction of cardiac muscl...x in human cells. It also cross-reacts with human ... Highly purified human cardiac troponin T This a...
Acl I (Psp1406 I) from New England Biolabs
Biology Products: